COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA

Clinical trials for COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA trials appear

Sign up with your email to follow new studies for COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug duo aims to stop aggressive liver Cancer's return

Disease control Not yet recruiting

This study is testing whether a combination of two drugs can help prevent a rare and aggressive type of liver cancer from returning after surgery. About 75 patients who have had their tumor removed but are at medium to high risk of it coming back will receive both an immunotherap…

Matched conditions: COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA

Get alerted when new COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA trials appear

New drug duo aims to stop aggressive liver Cancer's return